Toxicity and efficacy of busulfan-melphalan (BuMel) compared to treosulfan-melphalan (TreoMel) high dose chemotherapy (HDCT) consolidation in high-risk Ewing sarcoma (ES): A 12-year monoinstitutional experience.

Massimo Eraldo Abate,Anna Paioli,Marilena Cesari,Alessandra Longhi,Emanuela Palmerini,Elisabetta Setola,Elisa Carretta,Silvia Cammelli,L. Ronchi,Michele Rocca,Marco Manfrini,Katia Scotlandi,Davide Donati

Toxicity and efficacy of busulfan-melphalan (BuMel) compared to treosulfan-melphalan (TreoMel) high dose chemotherapy (HDCT) consolidation in high-risk Ewing sarcoma (ES): A 12-year monoinstitutional experience.

2019

Massimo Eraldo Abate
Anna Paioli
Marilena Cesari
Alessandra Longhi
Emanuela Palmerini
Elisabetta Setola
Elisa Carretta
Silvia Cammelli
L. Ronchi
Michele Rocca
Marco Manfrini
Katia Scotlandi
Davide Donati

e22507Background: We compared toxicity and outcomes of BuMel and TreoMel HDCT consolidation with stem cell rescue in high-risk ES pts prospectively treated in 5 consecutive trials at the Istituto O...

Keywords:

Toxicity
Oncology
Internal medicine
Sarcoma
Treosulfan
Busulfan/Melphalan
Stem cell rescue
Melphalan
Pathology
Chemotherapy
Medicine
high dose chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations